Product Description

VEGFD Monoclonal Antibody

Sizes: 50μl, 100μl

Catalogue Numbers: MB66725-50, MB66725-100

Lead times: 1-2 weeks, if manufacturer has product in stock

Manufacturer/Ship Location: China

Background: The onset of angiogenesis is believed to be an early event in tumorigenesis and may facilitate tumor progression and metastasis.Several growth factors with angiogenic activity have been described. These include fibroblast growth factor (FGF), platelet derived growth factor (PDGF) and vascμlar endothelial growth factor (VEGF). Several forms of VEGF have been identified, including VEGF, VEGF-B, VEGF-C and VEGF-D (also designated FIGF).Characteristic of VEGF proteins, the central region of VEGF-D contains eight cysteine residues.These residues are essential for homodimerization. VEGF-D may play a role in tumor progression, as it is induced by c-Fos, which is required for conversion of early stage tumors to malignant tumors. It has been observed that overexpression of VEGF-D induces morphological changes in fibroblasts.

Category: Primary Antibody

Reactivity: Human, Mouse

Host: Mouse

Applications: WB

Alternate Names: VEGFD, Vascμlar endothelial growth factor D, VEGF-D, c-Fos-induced growth factor, FIGF

Clonality: Monoclonal

Conjugate: Unconjugated

Modification: Unmodification

Immunogen: KLH-conjugated synthetic peptide encompassing a sequence within the C-term region of human VEGFD. The exact sequence is proprietary.

Dilution: WB (1/500 - 1/1000)

Purification: This antibody is purified through a protein G column.

Specificity: Recognizes endogenous levels of VEGFD protein.

Molecular Weight: ~ 40 kDa

Storage and Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

SwissProt: O43915

Product: Mouse IgG1. Liquid in PBS, pH 7.3, 30% glycerol, and 0.01% sodium azide.

Research Use Only